Single technology appraisal (STA)

Mirabegron for the treatment of symptoms associated with overactive bladder [ID542]

Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS.

Patients and patient advocates can provide a unique perspective on the technology, which is not typically available from the published literature.

To help you give your views, we have provided a template. The questions are there as prompts to guide you. You do not have to answer every question. Please do not exceed the 8-page limit.

_			_	_				
Λ	L	-		-4		-		
Δ	n	n	ι.	ıt	w	n	11	

Your name:

name: DOBBIE STUART

Name of your organisation:
Bladder & Bowla Fondshion

Are you (tick all that apply):


- a patient with the condition for which NICE is considering this technology?
- a carer of a patient with the condition for which NICE is considering this technology?
- an employee of a patient organisation that represents patients with the condition for which NICE is considering the technology? If so, give your position in the organisation where appropriate (e.g. policy officer, trustee, member, etc)
- other? (please specify)

Single technology appraisal (STA)

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition?

1. Advantages

(a) Please list the specific aspect(s) of the condition that you expect the technology to help with. For each aspect you list please describe, if possible, what difference you expect the technology to make.



- (b) Please list any short-term and/or long-term benefits that patients expect to gain from using the technology. These might include the effect of the technology on:
 - the course and/or outcome of the condition
 - physical symptoms
 - pain
 - level of disability
 - mental health
 - quality of life (lifestyle, work, social functioning etc.)
 - other quality of life issues not listed above
 - other people (for example family, friends, employers)
 - other issues not listed above.

A dignity
A QST Life

larg tom: - as short term
- Improved physical action
- V NSK of developing

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition? (continued)
 2. Disadvantages Please list any problems with or concerns you have about the technology. Disadvantages might include: aspects of the condition that the technology cannot help with or might make worse. difficulties in taking or using the technology side effects (please describe which side effects patients might be willing to accept or tolerate and which would be difficult to accept or tolerate) impact on others (for example family, friends, employers) financial impact on the patient and/or their family (for example cost of travel needed to access the technology, or the cost of paying a carer).
-Fractional incontinence will not be
- Easy to take with few Side effects - leading to good
- no francial impour on patral or fandy
Are there differences in opinion between patients about the usefulness or otherwise of this technology? If so, please describe them.
NOT KNOWN

Availability of this technology to patients in the NHS
What key differences, if any, would it make to patients and/or carers if this technology was made available on the NHS?
1/ Succossion could be used in Conjunction with Preis To Wear wised urinary incommense.
What implications would it have for patients and/or carers if the technology was not made available to patients on the NHS? Courtably the only with unscaring the debility of the effects
4) poor Complance
Are there groups of patients that have difficulties using the technology? Ho. Gorodly no, Minarch PS With

4. Are there any groups of patients who might benefit more from the ted others? Are there any groups of patients who might benefit less from the than others?			
Pts with overactive bladder on	y will		
bought the now. A's with with	de partir		
Comparing the technology with alternative available treatments or technologies	benefit.		
NICE is interested in your views on how the technology compares with treatments for this condition in the UK.	with existing		
(i) Please list any current standard practice (alternatives if any) used in			
	Many.		
PTNS SNS			
(ii) If you think that the new technology has any advantages for patients			
current standard practice, please describe them. Advantages might incl - improvement in the condition overall	ude:		
- improvement in certain aspects of the condition			
 ease of use (for example tablets rather than injection) where the technology has to be used (for example at home rather than injection) 	her than in		
hospital)			
 side effects (please describe nature and number of problems, for duration, severity etc.) 	requency,		
Many pts would prele to	be		
Good by taking a pl. 4	"sboncall		
College S	1 St Joseph		
these medications have to	CG See		
(iii) If you think that the new technology has any disadvantages for pat			
compared with current standard practice, please describe them. Disadv			
might include: - worsening of the condition overall			
- worsening of specific aspects of the condition			
 difficulty in use (for example injection rather than tablets) where the technology has to be used (for example in hospital rather than at 			
home)			
 side effects (for example nature or number of problems, how o long, how severe). 	ften, for how		

Single technology appraisal (STA)

Other Issues

Please include here any other issues you would like the Appraisal Committee to consider when appraising this technology.



Single technology appraisal (STA)

Are you aware of any research carried out on patient or carer views of the condition or existing treatments that is relevant to an appraisal of this technology? If yes, please provide references to the relevant studies.

Research evidence on patient or carer views of the technology
If you are familiar with the evidence base for the technology, please comment on whether patients' experience of using the technology as part of their routine NHS care reflects that observed under clinical trial conditions.
Are there any adverse effects that were not apparent in the clinical trials but have come to light since, during routine NHS care?
Not Known

Equality and Diversity
NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that this appraisal:
 Could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which [the treatment(s)] is/are/will be licensed; Could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology; Could lead to recommendations that have any adverse impact on people with a particular disability or disabilities
Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts
NA